Acute Toxicity of Vildagliptin

Area of Science:

• Pharmacology
• Toxicology
• Primate Studies

Background:

• Vildagliptin is a dipeptidyl peptidase-4 inhibitor used for type 2 diabetes.
• Understanding drug toxicity in preclinical models is crucial for human safety.

Purpose of the Study:

• To describe acute toxicity findings in cynomolgus monkeys after oral vildagliptin administration.
• To assess the relevance of observed toxicity to human safety.

Main Methods:

• Oral administration of vildagliptin to cynomolgus monkeys.
• Clinical observations, clinical pathology, and histopathology were used to assess toxicity.
• Comparison of toxicity between different cynomolgus monkey origins (Mauritius vs. Asian).

Main Results:

• Acute toxicity symptoms included edema, skeletal muscle necrosis, elevated liver enzymes, hypothermia, hypotension, and tachycardia.
• Symptoms were reversible in surviving animals.
• Mauritian cynomolgus monkeys showed higher sensitivity compared to Asian cynomolgus monkeys.

Conclusions:

• The observed acute toxicity is specific to cynomolgus monkeys.
• The underlying mechanism may involve vascular effects.
• Vildagliptin-induced acute toxicity in monkeys is not relevant to human safety.